Reusable Face Masks to Reduce Risk of Viral Respiratory Infections and Asthma Exacerbations

Reuseable Face Masks to Reduce Risk of Viral Respiratory Infections and Exacerbations in Adults With Asthma: a Randomised Controlled Trial

Status

Withdrawn

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06885229

Acronym

REMASK

Enrollment

Registered

2025-03-20

Start date

2025-03-27

Completion date

2025-04-01

Last updated

2025-05-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Respiratory Infection, Asthma Exacerbations

Keywords

Upper Respiratory Infection, Acute Respiratory Infection, Asthma Exacerbation, Lower Respiratory Infection, Reusable Face Mask

Brief summary

REMASK trial is a Trial within Cohort study (TwiCs), nested within the COVIDENCE UK longitudinal study. It has been designed to determine whether the offer of a free reusable, elastomeric face mask to adults with asthma and other members of their household reduces risk of RT-PCR confirmed viral respiratory infections and asthma exacerbations.

Interventions

DEVICEFloMask - reuseable face mask

Reuseable, elastomeric face mask with replaceable filters

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

16 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

Eligibility criteria, participants with asthma ('index participants'): Inclusion Criteria: * Aged 16 or more years * Doctor diagnosis of asthma * Current prescription for treatment of asthma * Participant in COVIDENCE UK nasal swab study

Exclusion criteria

* Regularly using any FFP-rated face mask when in an indoor public place * Currently sharing household with one or more children * Currently sharing household with one or more other COVIDENCE UK participants who have asthma * Unable to tolerate wearing face mask Eligibility criteria, household members of index participants: Inclusion criteria * Age 16 or more * Living in same household as index participant who has consented to take part in trial

Design outcomes

Primary

Measure	Time frame
Time to first RT-PCR-proven viral respiratory infection	12 months

Secondary

Measure	Time frame
Time to first hospitalisation for treatment of acute respiratory infection or asthma exacerbation	12 months
Time to first antibiotic prescription for treatment of acute respiratory infection	12 months
Time to first severe acute exacerbation of asthma (i.e. exacerbation requiring treatment with systemic corticosteroids and/or hospitalisation or emergency department visit)	12 months
Cost per viral respiratory infection averted	12 months
Cost per severe asthma exacerbation averted	12 months
Rate of RT-PCR-proven / symptom defined acute respiratory infections	12 months

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026